Human papillomavirus L1 protein and E7 oncoprotein (HPV L1 / E7)

The Human Papillomavirus (HPV) L1 protein and E7 oncoprotein are the primary targets for immunological and therapeutic interventions against HPV-related diseases. The L1 protein is the major structural component of the viral capsid and is the basis for prophylactic vaccines like Gardasil and Cervarix. These vaccines utilize L1-based virus-like particles (VLPs) to induce neutralizing antibodies that prevent the virus from infecting host cells. In contrast, the E7 oncoprotein is an early viral protein essential for the development and maintenance of HPV-induced malignancies. E7 promotes oncogenesis by binding to and inducing the degradation of the retinoblastoma tumor suppressor protein (pRb), which leads to uncontrolled cell cycle progression and genomic instability. Because E7 is constitutively expressed in HPV-driven cancers, such as cervical, anal, and oropharyngeal carcinomas, it is a key target for therapeutic vaccines and gene therapies designed to stimulate cytotoxic T-cell responses to eliminate existing lesions and tumors. While L1-targeted vaccines are highly effective at preventing infection, E7-targeted strategies are critical for treating established disease.

Other names

Major capsid protein L1Early protein E7HPV16 L1HPV16 E7HPV18 L1HPV18 E7HPV oncoprotein E7HPV capsid protein L1

Prophylactic vaccines targeting the L1 protein induce neutralizing antibodies that prevent viral entry and infection. Therapeutic strategies targeting the E7 oncoprotein aim to elicit cytotoxic T-cell responses to eliminate infected or transformed cells, or disrupt E7's interaction with the retinoblastoma protein (pRb) to restore cell cycle control.